Pharmadrug (TSE:PHRX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PharmaDrug Inc., through its subsidiary Sairiyo Therapeutics, is advancing the clinical development of PD-001, a patented reformulated version of Cepharanthine, aimed at treating a range of viral infectious diseases. After receiving ethics approval in Australia, the company is embarking on a Phase 1 clinical study, with hopes of progressing towards FDA approval. PD-001 is noted for its potential in combating viruses like Ebola and COVID-19, due to its enhanced bioavailability compared to existing formulations.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money